Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Movers and Shakers

- PMLiVE

Pfizer recalls depression drug in US

Wrong medicine found in bottle of Effexor XR

- PMLiVE

NICE relents and backs Pfizer’s Inlyta

Recommends drug to treat advanced kidney cancer on NHS in England

- PMLiVE

Novartis to close UK R&D site

Research operations at Horsham expected to end in June

- PMLiVE

LinkedIn adds a pharma ‘influencer’

Pfizer CEO Ian Read joins the likes of Bill Gates and Richard Branson in writing for the social network

UK flag

UK plans to reduce use of animals in research

Looks to new technologies to screen earlier for drug failures

- PMLiVE

Merck cuts MK-3475 deals with Pfizer, Amgen and Incyte

Sees combination potential for cancer prospect

- PMLiVE

Pfizer partners with Siemens on diagnostics

Will develop companion diagnostics to support clinical studies

- PMLiVE

NIH forges $230m research alliance with pharma

Brings 10 pharma companies together to speed up research in Alzheimer’s, diabetes and arthritis

- PMLiVE

A new option for people with HIV

ViiV Healthcare's dolutegravir could capture a significant share of the HIV market and may have blockbuster potential

- PMLiVE

Pfizer beats earnings estimates as new products grow

Lyrica, Inlyta and Xalkori help offset generic competition

- PMLiVE

Blow to Pfizer as dacomitinib fails in lung cancer trials

Unable to demonstrate improved survival in patients

- PMLiVE

ViiV wins European approval for Tivicay

HIV treatment licensed in combination with other anti-retroviral drugs

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links